Biotech News

Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics (CYTK)Cytokinetics2026-10-19 11:30 ESTFDA / regulatory

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) class II-III in adult patients. MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.

Cytokinetics

Muscle Biology Specialization Cytokinetics develops and commercializes medicines that modulate muscle function. Its portfolio is centered on cardiac muscle biology and diseases in which altered contractility contributes directly to symptoms and clinical outcomes. MYQORZO in Obstructive HCM MYQORZO, or aficamten, is a cardiac myosin...

Recent company news

CYTKCytokinetics2026-11-03 21:00 EST

Cytokinetics to Participate in November Investor Conferences

CYTKCytokinetics2026-11-02 12:30 EST

Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026

CYTKCytokinetics2026-10-21 20:00 EST

Cytokinetics to Announce Third Quarter Results on November 4, 2026

CYTKCytokinetics2026-10-19 20:00 EST

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CYTKCytokinetics2026-10-19 11:30 EST